Skip to content

Borderzone Sampling

Does Borderzone Contrast Enhancement on Intraoperative MRI During High Grade Glioma Resection Correlate With Residual Tumor?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00780819
Acronym
BZS
Enrollment
10
Registered
2008-10-28
Start date
2008-10-31
Completion date
2012-12-31
Last updated
2013-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, High Grade Glioma

Brief summary

On regular (diagnostic) MRI images brain tumors can show contrast enhancement: uptake of an intravenously administered contrast agent can cause an enhancement pattern that is seen as a white area on a frequently used MRI protocol (T1 weighted imaging). High grade gliomas are a common brain tumor that share this enhancement pattern. The goal of surgery is to resect this contrast enhancing part without causing additional neurological damage. Intraoperative MRI (iMRI) is a helpful tool in achieving this goal, because it can provide updated images during resection and correct for deformations that occur in the brain during surgery. These deformations make preoperative images that are used for standard neuronavigation systems less reliable. However, due to manipulations during surgery, the contrast uptake during surgery may differ from contrast uptake in diagnostic MRI. This study aims to relate contrast enhancement on iMRI and tumor characteristics on tissue samples from the tumor. When the neurosurgeon considers the resection of the high grade glioma to be complete, an iMRI scan will be made, and tissue sampling will be performed on the borderzones of the tumor or tumor resection cavity respectively. This will provide insight in the relation between contrast enhancement on iMRI and the presence of tumor tissue. Such knowledge is important to improve effectiveness and safety of iMRI guided brain tumor resection.

Interventions

DEVICEPoleStar N20 intraoperative MRI

low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* supratentorial brain tumor, on contrast enhanced MRI suspect for a high grade glioma * indication for resection of the tumor * age ≥ 18 years * WHO Performance Scale ≤ 2 * ASA class ≤ 3 * good knowledge of the Dutch language * informed consent

Exclusion criteria

* recurrent tumor * multiple tumor localizations * prior radiotherapy on the skull * prior chemotherapy

Design outcomes

Primary

MeasureTime frame
The relation between the shape and size of contrast enhancement on intraoperative MRI at the resection cavity border, and the presence of residual tumor tissue.after surgery, and after 1 year for additional immunochemistry

Secondary

MeasureTime frame
Survival (Kaplan Meier)after 4 years
Postoperative clinical condition (WHO Performance Scale)1 week after surgery
The relation between possible contrast enhancement and contrast enhancing tissue volume on the last intraoperative MRI scan and the early diagnostic MRI scanwithin 72 hours after surgery

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026